Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors

21 de julho de 2026 atualizado por: Jinsong Wu, Huashan Hospital

AI-Assisted Presurgical MRI Molecular Subtyping for Pediatric Brain Tumors: A Single-Center Ambispective Clinical Cohort Study

This multicenter observational cohort study aims to develop and validate an artificial intelligence (AI)-assisted diagnostic system for preoperative molecular subtyping of pediatric brain tumors using routine magnetic resonance imaging (MRI). The study will include seven major pediatric brain tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor (AT/RT), intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors.

The study includes a retrospective cohort for model development and internal/external validation, and a prospective cohort for further validation. Retrospective data will be collected from pediatric patients who underwent first surgical treatment between January 1, 2020 and December 31, 2025. Prospective enrollment will begin on July 15, 2026, with an anticipated sample size of 150 participants. The AI system will analyze preoperative MRI sequences, including T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR images, to predict key molecular markers and integrated diagnostic categories. The primary objective is to evaluate the diagnostic performance of the AI system for prespecified molecular prediction tasks using postoperative histopathology and molecular testing as the reference standard. Secondary objectives include assessing agreement with integrated diagnosis, comparing performance against blinded radiologists, and exploring prognostic associations of AI-predicted subgroups.

Visão geral do estudo

Descrição detalhada

Pediatric brain tumors are the most common solid tumors in children and represent a highly heterogeneous group of diseases with marked variation in histology, molecular alterations, anatomic location, treatment response, and prognosis. Several molecular features, including H3K27M mutation, BRAF V600E mutation, ZFTA fusion, SMARCB1 loss, CTNNB1 mutation, and TP53 alteration, are clinically important for diagnostic classification, risk stratification, prognosis assessment, and treatment planning. However, most molecular characterization currently depends on postoperative tissue-based testing, and noninvasive preoperative prediction remains limited.

This study is designed to evaluate an AI-assisted MRI-based diagnostic system for pediatric brain tumors in a real-world multicenter observational setting. The study will include seven target tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors. The retrospective component will collect multimodal data, including clinical variables, preoperative MRI, pathology reports, molecular testing results, treatment information, and follow-up data, from eligible pediatric patients treated from January 1, 2020 through December 31, 2025. The prospective component will consecutively enroll eligible patients from July 15, 2026 onward for additional validation of model performance.

Preoperative MRI data will be preprocessed using standardized procedures, including bias field correction, skull stripping, isotropic resampling, and intensity normalization. The AI model will be developed to support classification of tumor type and prediction of key molecular subtypes/markers from presurgical MRI. Model performance will be evaluated using postoperative pathology and molecular testing as the reference standard. The primary endpoint is the area under the receiver operating characteristic curve (AUC) for prespecified molecular prediction tasks. Secondary analyses will evaluate agreement between AI output and integrated final diagnosis, comparative performance against blinded radiologists on independent test sets, multiclass tumor classification performance, biomarker-specific sensitivity and specificity, and progression-free survival stratified by AI-predicted subgroup.

This study is observational and is not intended for medical device registration. Biospecimen banking is not a registration objective of this study.

Tipo de estudo

Observacional

Inscrição (Estimado)

1400

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Lei Jin
  • Número de telefone: 86-21-52887200
  • E-mail: ozlei91@126.com

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

Pediatric patients with suspected primary brain tumors who undergo first surgical treatment at participating centers and whose postoperative pathology confirms one of seven predefined tumor categories.

Descrição

Inclusion Criteria:

  • Age younger than 18 years at the time of index surgery.
  • Evaluated at a participating study center and scheduled for first surgical treatment of a suspected target pediatric brain tumor.
  • Preoperative brain MRI available before surgery, including at minimum T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR sequences in DICOM format; MRI preferably performed within 7 days before surgery and before biopsy or tumor-directed therapy.
  • Postoperative histopathology confirming one of the following target tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, or choroid plexus tumors.
  • For the prospective cohort, written informed consent provided by a parent or legal guardian, with child assent obtained when appropriate according to age, understanding, and local ethics requirements.

Exclusion Criteria:

  • Postoperative pathology confirming a non-target tumor type.
  • Recurrent tumor, repeat surgery, or prior tumor-directed surgery before the index surgery.
  • Preoperative MRI of inadequate quality for analysis, including severe motion artifact, severe susceptibility/metal artifact, or incomplete field of view.
  • Prior biopsy, radiotherapy, chemotherapy, or other tumor-directed treatment before the index preoperative MRI that is judged to substantially affect imaging interpretation.
  • Concurrent malignant disease other than the target brain tumor.
  • Inability to comply with follow-up requirements in the prospective cohort, in the investigator's judgment, because of severe comorbidity or other practical limitations.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Retrospective Cohort
Pediatric patients younger than 18 years who underwent first surgical treatment for one of the target brain tumors between January 1, 2020 and December 31, 2025, with available preoperative MRI and postoperative pathological confirmation. Data from this cohort will be used for model development and validation.
Prospective Cohort
Consecutively enrolled pediatric patients younger than 18 years meeting eligibility criteria from July 15, 2026 onward. Data from this cohort will be used for prospective validation of AI diagnostic performance.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Area Under the Receiver Operating Characteristic Curve (AUC) for MRI-Based Prediction of Prespecified Molecular Markers
Prazo: Assessed at final model evaluation using all eligible retrospective cases collected from January 1, 2020 through December 31, 2025 and all eligible prospectively enrolled cases with available reference-standard data collected from July 15, 2026 through D
Diagnostic discrimination of the AI-assisted system for binary prediction of prespecified key molecular markers or molecular subtypes from preoperative MRI, using postoperative histopathology and molecular testing as the reference standard. AUC values and 95% confidence intervals will be calculated for each prespecified molecular prediction task.
Assessed at final model evaluation using all eligible retrospective cases collected from January 1, 2020 through December 31, 2025 and all eligible prospectively enrolled cases with available reference-standard data collected from July 15, 2026 through D

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Agreement Between AI-Based Diagnosis and Integrated Final Diagnosis
Prazo: Assessed at final diagnostic adjudication for each eligible participant from study start on July 15, 2026 through study completion on December 30, 2029, including retrospective cases with complete reference-standard data.
Agreement between AI-predicted diagnostic output based on preoperative MRI and the integrated final diagnosis established from imaging, postoperative histopathology, and molecular testing. Agreement will be quantified using Cohen's kappa coefficient.
Assessed at final diagnostic adjudication for each eligible participant from study start on July 15, 2026 through study completion on December 30, 2029, including retrospective cases with complete reference-standard data.
Comparative Diagnostic Performance of the AI System Versus Blinded Radiologists
Prazo: Assessed at blinded reader evaluation after completion of dataset curation and test set locking, anticipated by December 30, 2029.
Comparison of sensitivity, specificity, accuracy, and AUC between the AI system and radiologists blinded to pathology and molecular results on a predefined independent test dataset.
Assessed at blinded reader evaluation after completion of dataset curation and test set locking, anticipated by December 30, 2029.
Macro-Average AUC for Seven-Class Tumor Classification
Prazo: Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Macro-average area under the receiver operating characteristic curve for classification of the seven target pediatric brain tumor categories.
Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Weighted F1 Score for Seven-Class Tumor Classification
Prazo: Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Weighted F1 score of the AI system for multiclass classification across glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors.
Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Sensitivity and Specificity for Prediction of Key Molecular Biomarkers
Prazo: Assessed at final model evaluation using cases with complete biomarker reference-standard results through December 30, 2029.
Sensitivity and specificity of the AI system for prediction of tumor-specific biomarkers, including but not limited to H3K27M mutation, BRAF V600E mutation, ZFTA fusion, SMARCB1 loss, CTNNB1 mutation, and TP53 alteration, depending on tumor type and data availability.
Assessed at final model evaluation using cases with complete biomarker reference-standard results through December 30, 2029.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de julho de 2026

Conclusão Primária (Estimado)

30 de dezembro de 2029

Conclusão do estudo (Estimado)

30 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

8 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de julho de 2026

Primeira postagem (Real)

14 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

21 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever